155 related articles for article (PubMed ID: 31836609)
1. Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER
Robertson JFR; Coleman RE; Cheung KL; Evans A; Holcombe C; Skene A; Rea D; Ahmed S; Jahan A; Horgan K; Rauchhaus P; Littleford R; Cheung SYA; Cullberg M; de Bruin EC; Koulai L; Lindemann JPO; Pass M; Rugman P; Schiavon G; Deb R; Finlay P; Foxley A; Gee JMW
Clin Cancer Res; 2020 Apr; 26(7):1574-1585. PubMed ID: 31836609
[TBL] [Abstract][Full Text] [Related]
2. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M
Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in
Banerji U; Dean EJ; Pérez-Fidalgo JA; Batist G; Bedard PL; You B; Westin SN; Kabos P; Garrett MD; Tall M; Ambrose H; Barrett JC; Carr TH; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Elvin P; Foxley A; Lawrence P; Lindemann JPO; Maudsley R; Pass M; Rowlands V; Rugman P; Schiavon G; Yates J; Schellens JHM
Clin Cancer Res; 2018 May; 24(9):2050-2059. PubMed ID: 29066505
[No Abstract] [Full Text] [Related]
4. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
[TBL] [Abstract][Full Text] [Related]
5. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Crabb SJ; Griffiths G; Marwood E; Dunkley D; Downs N; Martin K; Light M; Northey J; Wilding S; Whitehead A; Shaw E; Birtle AJ; Bahl A; Elliott T; Westbury C; Sundar S; Robinson A; Jagdev S; Kumar S; Rooney C; Salinas-Souza C; Stephens C; Khoo V; Jones RJ
J Clin Oncol; 2021 Jan; 39(3):190-201. PubMed ID: 33326257
[TBL] [Abstract][Full Text] [Related]
6. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Kolinsky MP; Rescigno P; Bianchini D; Zafeiriou Z; Mehra N; Mateo J; Michalarea V; Riisnaes R; Crespo M; Figueiredo I; Miranda S; Nava Rodrigues D; Flohr P; Tunariu N; Banerji U; Ruddle R; Sharp A; Welti J; Lambros M; Carreira S; Raynaud FI; Swales KE; Plymate S; Luo J; Tovey H; Porta N; Slade R; Leonard L; Hall E; de Bono JS
Ann Oncol; 2020 May; 31(5):619-625. PubMed ID: 32205016
[TBL] [Abstract][Full Text] [Related]
7. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
[TBL] [Abstract][Full Text] [Related]
8. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
9. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
[TBL] [Abstract][Full Text] [Related]
10. "The emerging role of capivasertib in breast cancer".
Andrikopoulou A; Chatzinikolaou S; Panourgias E; Kaparelou M; Liontos M; Dimopoulos MA; Zagouri F
Breast; 2022 Jun; 63():157-167. PubMed ID: 35398754
[TBL] [Abstract][Full Text] [Related]
11. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
12. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
13. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
[TBL] [Abstract][Full Text] [Related]
15. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
16. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
Pervanidis KA; D'Angelo GD; Weisner J; Brandherm S; Rauh D
J Med Chem; 2024 Apr; 67(8):6052-6063. PubMed ID: 38592948
[TBL] [Abstract][Full Text] [Related]
17. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
Kalinsky K; Sparano JA; Zhong X; Andreopoulou E; Taback B; Wiechmann L; Feldman SM; Ananthakrishnan P; Ahmad A; Cremers S; Sireci AN; Cross JR; Marks DK; Mundi P; Connolly E; Crew KD; Maurer MA; Hibshoosh H; Lee S; Hershman DL
Clin Transl Oncol; 2018 Nov; 20(11):1474-1483. PubMed ID: 29736694
[TBL] [Abstract][Full Text] [Related]
18. Circumventing AKT-Associated Radioresistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capivasertib.
Lang L; Lam T; Chen A; Jensen C; Duncan L; Kong FC; Kurago ZB; Shay C; Teng Y
Cells; 2020 Feb; 9(3):. PubMed ID: 32106632
[TBL] [Abstract][Full Text] [Related]
19. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
20. AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
